Johnson & Johnson’s

Animas rebuked for not reporting insulin pump mishaps

A Johnson & Johnson subsidiary could face penalties for not reporting incidents where insulin pumps failed to operate, according to a recent letter from the Food and Drug Administration. The correspondence also alleged that Animas Corp. failed to establish an adequate system for reporting medical device mishaps.

The verdict is in: Johnson & Johnson misled physicians in Risperdal marketing campaign

A jury in South Carolina on Tuesday found Johnson & Johnson's pharmaceutical unit, Ortho-McNeil-Janssen, guilty of misleading doctors about the safety and effectiveness of the anti-psychotic drug Risperdal.